| Literature DB >> 35049926 |
Xia-Yu Chen1,2, Qi Zeng1,2, Yu-Chan Chen3, Wei-Mao Zhong1, Yao Xiang1,2, Jun-Feng Wang1, Xue-Feng Shi1, Wei-Min Zhang3, Si Zhang1, Fa-Zuo Wang1.
Abstract
Six new α-pyrone meroterpenoid chevalones H-M (1-6), together with six known compounds (7-12), were isolated from the gorgonian coral-derived fungus Aspergillus hiratsukae SCSIO 7S2001 collected from Mischief Reef in the South China Sea. Their structures, including absolute configurations, were elucidated on the basis of spectroscopic analysis and X-ray diffraction data. Compounds 1-5 and 7 showed different degrees of antibacterial activity with MIC values of 6.25-100 μg/mL. Compound 8 exhibited potent cytotoxicity against SF-268, MCF-7, and A549 cell lines with IC50 values of 12.75, 9.29, and 20.11 μM, respectively.Entities:
Keywords: Aspergillus hiratsukae; antibacterial activity; coral-derived fungi; cytotoxic activity; meroterpenoids
Mesh:
Substances:
Year: 2022 PMID: 35049926 PMCID: PMC8781156 DOI: 10.3390/md20010071
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–12.
1H NMR (700 MHz) and 13C NMR (176 MHz) data for compounds 1–3.
| NO. | 1 a | 2 a | 3 a | |||
|---|---|---|---|---|---|---|
| 1 | 78.1 CH | 3.51 m | 77.7 CH | 3.54 dd (11.4, 4.6) | 76.4 CH | 3.63 dd (11.2, 4.8) |
| 2 | 34.5 CH2 | 1.69–1.72 m | 34.5 CH2 | 1.67–1.71 m | 33.5 CH2 | 1.93–1.95 m |
| 1.89 dt (12.3, 4.5) | 1.90 dt (12.5, 4.4) | 1.80–1.82 m | ||||
| 3 | 77.3 CH | 4.47 dd (12.2, 4.4) | 77.2 CH | 4.48 dd (12.2, 4.3) | 77.3 CH | 4.45 dd (12.3, 4.2) |
| 4 | 37.9 C | 37.9 C | 37.7 C | |||
| 5 | 53.3 CH | 0.74–0.78 m | 53.3 CH | 0.76 dd (12.1, 2.5) | 54.4 CH | 0.80 dd (12.4, 2.4) |
| 6 | 17.4 CH2 | 1.58–1.60 m | 17.6 CH2 | 1.56–1.58 m | 18.1 CH2 | 1.06–1.08 m |
| 1.66–1.68 m | 1.61–1.63 m | 1.23–1.25 m | ||||
| 7 | 40.5 CH2 | 1.18–1.21 m | 40.8 CH2 | 0.98–1.04 m | 42.0 CH2 | 1.18–1.20 m |
| 2.16–2.18 m | 1.85 dt (12.9, 3.4) | 2.15–2.17 m | ||||
| 8 | 39.6 C | 38.2 C | 39.6 C | |||
| 9 | 61.6 CH | 1.04 dd (11.7, 2.4) | 61.1 CH | 1.10 dd (12.1, 2.4) | 61.5 CH | 0.88 d (3.1) |
| 10 | 43.5 C | 43.5 C | 44.1 C | |||
| 11 | 21.6 CH2 | 1.60–1.62 m | 21.4 CH2 | 1.43–1.45 m | 70.0 CH | 4.79 dt (5.4, 2.7) |
| 2.65–2.69 m | 2.64–2.70 m | |||||
| 12 | 41.8 CH2 | 1.64–1.66 m | 40.6 CH2 | 1.63–1.65 m | 48.7 CH2 | 1.87–1.89 m |
| 2.02 dt (11.9, 3.1) | 2.00–2.04 m | 2.28–2.30 m | ||||
| 13 | 81.9 C | 80.4 C | 81.3 C | |||
| 14 | 56.5 CH | 1.42 d (4.1) | 52.1 CH | 1.46 d (4.5) | 56.6 CH | 1.41 d (4.0) |
| 15 | 60.5 CH | 4.89 d (4.0) | 17.0 CH2 | 2.13 dd (16.7, 13.0) | 60.2 CH | 4.95 d (4.0) |
| 2.42 dd (16.7, 4.7) | ||||||
| 16 | 22.1 CH3 | 1.57 s | 20.6 CH3 | 1.19 s | 23.1 CH3 | 1.77 s |
| 17 | 18.3 CH3 | 1.33 s | 16.4 CH3 | 0.90 s | 19.6 CH3 | 1.69 s |
| 18 | 12.4 CH3 | 0.95 s | 12.4 CH3 | 0.92 s | 14.9 CH3 | 1.29 s |
| 19 | 28.0 CH3 | 0.85 s | 27.9 CH3 | 0.84 s | 27.8 CH3 | 0.84 s |
| 20 | 16.2 CH3 | 0.86 s | 16.1 CH3 | 0.85 s | 16.0 CH3 | 0.88 s |
| 2′ | 165.6 C | 165.6 C | 165.6 C | |||
| 3′ | 101.4 C | 97.9 C | 101.4 C | |||
| 4′ | 163.4 C | 163.5 C | 163.0 C | |||
| 5′ | 101.1 CH | 5.73 s | 100.8 CH | 5.68 s | 101.0 CH | 5.73 s |
| 6′ | 161.6 C | 159.9 C | 161.7 C | |||
| 7′ | 20.0 CH3 | 2.19 s | 19.9 CH3 | 2.17 s | 20.0 CH3 | 2.19 s |
| 1″ | 171.0 C | 171.0 C | 171.0 C | |||
| 2″ | 21.3 CH3 | 2.05 s | 21.3 CH3 | 2.05 s | 21.3 CH3 | 2.06 s |
a The solvent was CDCl3.
Figure 2Key HMBC and COSY correlations of compounds 1–6.
Figure 3Key NOESY correlations of compounds 1–6.
Figure 4Experimental ECD spectra of compounds 1 and 2.
Figure 5X-ray ORTEP diagram of compounds 1 and 2.
1H NMR (700 MHz) and 13C NMR (176 MHz) data for compounds 4–6.
| NO. | 4 a | 5 b | 6 b | |||
|---|---|---|---|---|---|---|
| 1 | 76.7 CH | 3.59 dd (11.2, 4.9) | 78.9 CH | 3.82 dd (11.1, 5.1) | 33.7 CH2 | 1.73–1.75 m |
| 0.93–0.95 m | ||||||
| 2 | 34.0 CH2 | 1.82–1.84 m | 34.7 CH2 | 1.95–1.98 m | 24.7 CH2 | 1.64–1.69 m |
| 1.89 m | 1.98–2.00 m | |||||
| 3 | 79.0 CH | 4.48 dd (12.3, 4.3) | 77.2 CH | 4.44 dd (12.1, 4.7) | 82.4 CH | 4.49 dd (11.8, 4.7) |
| 4 | 38.7 C | 37.5 C | 38.7 C | |||
| 5 | 55.0 CH | 0.91 dd (6.3, 1.8) | 53.8 CH | 0.85–0.87 m | 57.3 CH | 1.07–1.09 m |
| 6 | 19.2 CH2 | 1.67–1.69 m | 17.9 CH2 | 1.53–1.55 m | 18.6 CH2 | 1.56–1.60 m |
| 1.76 dd (12.8, 3.7) | 1.61–1.63 m | 2.16 dd (16.6, 13.0) | ||||
| 7 | 43.5 CH2 | 1.09–1.12 m | 41.8 CH2 | 1.05–1.07 m | 42.7 CH2 | 1.14–1.18 m |
| 1.80–1.82 m | 1.93 dt (13.0, 3.5) | 1.89–1.94 m | ||||
| 8 | 39.0 C | 38.4 C | 38.6 C | |||
| 9 | 61.6 CH | 1.08 d (2.9) | 62.8 CH | 1.18–1.20 m | 62.4 CH | 1.06–1.07 m |
| 10 | 45.2 C | 47.4 C | 43.3 C | |||
| 11 | 70.6 CH | 4.84–4.86 m | 24.4 CH2 | 2.04–2.06 m | 22.8 CH2 | 1.88–1.90 m |
| 2.68–2.70 m | ||||||
| 12 | 47.9 CH2 | 1.90–1.94 m | 41.7 CH2 | 1.51–1.53 m | 42.6 CH2 | 2.01–2.03 m |
| 2.24–2.26 m | 2.00–2.02 m | 1.51–1.53 m | ||||
| 13 | 81.5 C | 80.5 C | 82.3 C | |||
| 14 | 53.2 CH | 1.56 dd (12.8, 4.7) | 52.5 CH | 1.44 dd (12.9, 4.8) | 53.5 CH | 1.50–1.51 m |
| 15 | 17.4 CH2 | 2.40 dd (16.6, 4.8) | 17.2 CH2 | 2.16–2.18m | 17.8 CH2 | 2.39 dd (16.7, 4.7) |
| 2.43 dd (16.7, 4.8) | 1.28–1.32 m | |||||
| 16 | 22.0 CH3 | 1.42 s | 20.1 CH3 | 1.21 s | 20.6 CH3 | 1.23 s |
| 17 | 18.2 CH3 | 1.27 s | 15.5 CH3 | 1.10 s | 16.1 CH3 | 1.10 s |
| 18 | 15.3 CH3 | 1.28 s | 63.5 CH2 | 4.27 d (12.1) | 62.1 CH2 | 3.85 d (12.0) |
| 3.90 d (12.2) | 3.97 d (12.0) | |||||
| 19 | 28.0 CH3 | 0.84 s | 28.2 CH3 | 0.84 s | 29.1 CH3 | 0.89 s |
| 20 | 16.3 CH3 | 0.89 s | 16.2 CH3 | 0.81 s | 17.3 CH3 | 0.87 s |
| 2′ | 167.5 C | 165.5 C | 167.6 C | |||
| 3′ | 98.7 C | 97.8 C | 98.7 C | |||
| 4′ | 165.3 C | 163.5 C | 165.7 C | |||
| 5′ | 102.1 CH | 5.89 s | 100.8 CH | 5.68 s | 102.1 CH | 5.89 s |
| 6′ | 161.8 C | 160.0 C | 161.8 C | |||
| 7′ | 19.5 CH3 | 2.20 s | 19.9 CH3 | 2.19 s | 19.5 CH3 | 2.20 s |
| 1″ | 172.6 C | 171.1 C | 172.8 C | |||
| 2″ | 21.0 CH3 | 2.04 s | 21.3 CH3 | 2.06 s | 21.1 CH3 | 2.03 s |
a The solvent was CD3OD, b the solvent was CDCl3.
The antibacterial activities of compounds 1–12.
| Compounds | MIC (μg/mL) | |||
|---|---|---|---|---|
|
|
| Methicillin-Resistant |
| |
|
| 6.25 | 50 | 6.25 | 6.25 |
|
| 25 | >100 | 6.25 | 25 |
|
| 25 | 25 | 12.5 | >100 |
|
| >100 | 6.25 | 25 | 50 |
|
| 12.5 | >100 | 12.5 | 12.5 |
|
| >100 | >100 | >100 | >100 |
|
| >100 | 50 | >100 | 12.5 |
|
| >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 |
|
| >100 | >100 | >100 | >100 |
| Ciprofloxacin | 0.25 | 0.25 | 0.50 | 0.50 |
Cytotoxic activity of compounds (1–12) against tumor cells.
| Compounds | IC50 (μM) | |||
|---|---|---|---|---|
| SF-268 | MCF-7 | HepG-2 | A549 | |
|
| >128 | >128 | >128 | >128 |
|
| 65.64 ± 0.53 | 91.69 ± 6.59 | 107.31 ± 9.83 | 84.54 ± 16.23 |
|
| >128 | >128 | >128 | >128 |
|
| >128 | >128 | >128 | >128 |
|
| 54.78 ± 3.18 | 56.28 ± 2.05 | 58.54 ± 1.52 | 55.33 ± 1.60 |
|
| >128 | >128 | >128 | >128 |
|
| >128 | >128 | >128 | >128 |
|
| 12.75 ± 1.43 | 9.29 ± 0.80 | >128 | 20.11 ± 2.31 |
|
| >128 | >128 | >128 | >128 |
|
| >128 | >128 | >128 | >128 |
|
| >128 | >128 | >128 | >128 |
|
| >128 | >128 | >128 | >128 |
| Adriamycin | 1.94 ± 0.01 | 2.00 ± 0.04 | 2.16 ± 0.05 | 2.16 ± 0.07 |